Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915

NOVO NORDISK AS

(NOVO B)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/12/2019 09/13/2019 09/16/2019 09/17/2019 09/18/2019 Date
342.25(c) 336.65(c) 334(c) 344.3(c) 343.05 Last
2 667 215 2 774 737 2 114 225 2 791 865 423 365 Volume
-0.10% -1.64% -0.79% +3.08% -0.36% Change
More quotes
Financials (DKK)
Sales 2019 120 B
EBIT 2019 52 483 M
Net income 2019 39 131 M
Finance 2019 11 776 M
Yield 2019 2,45%
Sales 2020 128 B
EBIT 2020 55 459 M
Net income 2020 43 822 M
Finance 2020 13 738 M
Yield 2020 2,68%
P/E ratio 2019 21,0x
P/E ratio 2020 18,4x
EV / Sales2019 6,67x
EV / Sales2020 6,27x
Capitalization 815 B
More Financials
Company
Novo Nordisk specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84%); - hemophilia treatment products (8.6%): mainly injections of protein; - growth hormones (6.1%):... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk AS
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK AS
09/17NOVO NORDISK : Oral semaglutide improves glycaemic control in people with type 2..
PU
09/17NOVO NORDISK A/S : - Securities lawsuit filed in Denmark against Novo Nordisk
AQ
09/16NOVO NORDISK : A/S – Share repurchase programme
PU
09/16NOVO NORDISK : Disclosure of transaction data
PU
09/10NEW INTERNATIONAL STUDY : The hidden burden of diabetes on family members reveal..
AQ
09/09NOVO NORDISK : Disclosure of transaction data
PU
09/09NOVO NORDISK A/S : – Share repurchase programme
AQ
09/02NOVO NORDISK : A/S – Share repurchase programme
PU
09/02NOVO NORDISK : Disclosure of transaction data
PU
08/27ASTRAZENECA : U.S. FDA gives fast track status to AstraZeneca's diabetes drug Fa..
RE
More news
Analyst Recommendations on NOVO NORDISK AS
More recommendations
Stock Trading Strategies
NOVO NORDISK AS - 07/18
The underlying trend is in force again
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
02:32aAstraZeneca Amends China Collaboration Agreement With Ironwood
DJ
09/17ALEXION PHARMACEUTICALS : Names New Finance Chief
DJ
09/17ABBVIE : Form 8.3 - Allergan Plc
DJ
09/17BAYER : Invests $20 Million in U.S.-Based Informed Data Systems
DJ
09/17Merck Gets FDA Priority Review for Investigational Ebola Zaire Virus Vaccine
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVO NORDISK AS
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 363,50  DKK
Last Close Price 344,30  DKK
Spread / Highest target 30,7%
Spread / Average Target 5,58%
Spread / Lowest Target -35,2%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS15.58%120 613
JOHNSON & JOHNSON0.38%342 221
ROCHE HOLDING LTD.12.28%240 139
MERCK AND COMPANY7.98%211 257
PFIZER-16.38%201 883
NOVARTIS16.65%198 222